A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

Official Title: “A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty”

The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).

Study Design:

A total of 80 children with confirmed CPP were planned to be enrolled and randomized in a 1:1 ratio to receive 2 injections of either leuprolide acetate 11.25 mg or 30 mg depot formulation, each injection administered 3 mo apart (6 mo of treatment):

This study includes a 4-week Screening Period, two 3-mo treatment cycles, and a posttreatment follow-up period (12 weeks following the Mo 6 visit). Study visits will occur at Screening, Day 1, Week 2 (only for subjects participating in the pharmacokinetic subset), Mo 1, 2, 3, Mo 6/Early Termination, and 12 weeks later, for the Posttreatment Follow-up Visit.

This study was conducted at 18 sites in the United States and 4 sites in Puerto Rico.

Intervention(s) in this Clinical Trial

• Drug: Leuprolide acetate 11.25 mg
  • Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
• Drug: Leuprolide acetate 30 mg
  • Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Leuprolide acetate 11.25 mg
  • There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
• Experimental: Leuprolide acetate 30 mg
  • There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.

Primary Measures

• Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6
  • Time Frame: Month 2 through 6
    Safety Issue?: No

Secondary Measures

• Percentage of Participants With Suppression of Basal Estradiol <20 pg/mL by Visit
  • Time Frame: Month 1, 2, 3 and 6
    Safety Issue?: No
• Percentage of Participants With Suppression of Testosterone in <30 ng/dL by Visit
  • Time Frame: Month 1, 2, 3 and 6
    Safety Issue?: No
• Peak-stimulated Luteinizing Hormone Concentration by Visit
  • Time Frame: Baseline, Month 1, 2, 3 and 6
    Safety Issue?: No
• Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6
  • Time Frame: Month 6
    Safety Issue?: No
• Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6
  • Time Frame: Month 6
    Safety Issue?: No
• Change From Baseline in Incremental Growth Rate (cm/Year) at Month 6
  • Time Frame: Baseline and Month 6
    Safety Issue?: No
• Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6
  • Time Frame: Baseline to Month 6
    Safety Issue?: No

Inclusion Criteria:

• Subject has a clinical diagnosis of CPP.
• Eligible to receive at least 6 mo of therapy to treat CPP after study entry.
• Bone age advanced at least 1 year beyond the chronological age at time of diagnosis or first treatment.
• In general good health with no uncontrolled, clinically significant disease which would interfere with bone maturation or mask the objectives of this protocol as assessed by the investigator.

Additional criteria for subjects who have not had previous treatment:

• Girls 2-8 years inclusive or Boys 2-9 years inclusive at Day 1.
• Has pretreatment pubertal response to leuprolide acetate stimulation (luteinizing hormone ≥8 mIU/mL) at Screening.
• Breast pubertal staging of at least 2 in girls; testicular volume of at least 4 cc or testicular length greater than 2.5 cm in boys at Screening.

Additional criteria for subjects previously treated:

• Girls 2-10 years inclusive or boys 2-11 years inclusive at Day 1.
• Must have been on standard gonadotropin releasing hormone analog therapy for at least the 6 mo prior to Day 1.
• Has documented maintenance of luteinizing hormone suppression as evidenced by peak stimulated level <4 mIU/mL at Screening.

Exclusion Criteria:

• Incomplete precocious puberty (premature thelarche, premature adrenarche).
• Peripheral precocious puberty: gonadal or adrenal tumors, congenital adrenal hyperplasia, testotoxicosis in boys, human chorionic gonadotropin secreting tumor or McCune-Albright syndrome in girls.
• Evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid and gonadal function other than premature secretion of gonadotropins not adequately controlled.
• Unstable intracranial tumors (unresponsive to treatment/expanding) except hamartoma.
• Previous treatment with GnRHa therapy requiring leuprolide acetate for depot suspension >15 mg monthly.
• Bone age >13 years for girls and >14 years for boys.
• Any other condition interfering with growth, ie, skeletal dysplasia, cerebral palsy.
• Chronic illness requiring treatment that may interfere with growth, ie, chronic steroid use, renal failure, moderate to severe scoliosis.
• Diagnosis of short stature, ie more than 2.25 standard deviations below the mean height for age (growth chart measurement).
• Prior or current therapy with medroxyprogesterone acetate or growth hormone.
• Has an abnormal laboratory value suggesting a clinically significant underlying disease .
• Creatinine >1.5 mg/dL, alanine aminotransferase and/or aspartate aminotransferase
• >2.0 x upper limit of normal, or total bilirubin >2.0 mg/dL with aspartate aminotransferase/alanine aminotransferase elevated above normal limits.
• Positive pregnancy test.
• Known hypersensitivity to study medication or its excipients.
• Participation in another drug research within 3 mo of enrollment into this study.
• Prior or current therapy with insulin-like growth factor-1.
• Use of an estrogen preparation within 2 mo prior to Day 1.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 2 Years

Maximum Age for this Clinical Trial: 11 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Abbott Industry

Overall Clinical Trial Officials and Contacts

Peter Bacher, MD, Study Director Abbott  

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00635817

Study ID Number: L-CP07-167

ClinicalTrials.gov Identifier: NCT00635817

Health Authority: United States: Food and Drug Administration